Interestingly, when the authors introduced a double knockout of Zeb2 and Zeb1 in this same MLL-AF9 model they did not observe any further delay in tumor onset suggesting that Zeb1 loss was could not compound the effect of Zeb2 loss alone. This evidence concerns the gene KMT2A and neoplasm.